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ABSTRACT
Purpose Optical coherence tomography (OCT) captures 
retinal damage in neuromyelitis optica spectrum disorders 
(NMOSD). Previous studies investigating OCT in NMOSD 
have been limited by the rareness and heterogeneity of the 
disease. The goal of this study was to establish an image 
repository platform, which will facilitate neuroimaging 
studies in NMOSD. Here we summarise the profile of the 
Collaborative OCT in NMOSD repository as the initial effort 
in establishing this platform. This repository should prove 
invaluable for studies using OCT to investigate NMOSD.
Participants The current cohort includes data from 539 
patients with NMOSD and 114 healthy controls. These 
were collected at 22 participating centres from North and 
South America, Asia and Europe. The dataset consists of 
demographic details, diagnosis, antibody status, clinical 
disability, visual function, history of optic neuritis and other 
NMOSD defining attacks, and OCT source data from three 
different OCT devices.
Findings to date The cohort informs similar demographic 
and clinical characteristics as those of previously published 
NMOSD cohorts. The image repository platform and centre 
network continue to be available for future prospective 
neuroimaging studies in NMOSD. For the conduct of the 
study, we have refined OCT image quality criteria and 
developed a cross- device intraretinal segmentation pipeline.
Future plans We are pursuing several scientific projects 
based on the repository, such as analysing retinal layer 
thickness measurements, in this cohort in an attempt to 
identify differences between distinct disease phenotypes, 
demographics and ethnicities. The dataset will be available 
for further projects to interested, qualified parties, such 
as those using specialised image analysis or artificial 
intelligence applications.
Strengths and limitations of this study
 ► The Collaborative OCT in neuromyelitis optical spec-
trum disorders repository cohort comprises the larg-
est number of retinal optical coherence tomography 
(OCT) images from patients with a neuromyelitis 
spectrum disorder, a rare autoimmune disease of 
the central nervous system.
 ► Besides imaging data, information on clinical and 
functional scores as well as laboratory parameters 
were assessed.
 ► We collect OCT images as original files, allowing for 
a detailed quality reading and standardised, device- 
independent OCT analysis.
 ► Despite standardised image analysis, the image het-
erogeneity due to different OCT machines and scan 
protocols remains a challenge.
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INTRODUCTION
Neuromyelitis optical spectrum disorders (NMOSD) are 
rare autoimmune neuroinflammatory diseases spanning 
a broad age range. They are clinically characterised by 
recurrent attacks of optic neuritis (ON), myelitis and less 
frequently by the brainstem and cerebral attacks, and 
profoundly impact patients’ quality of life.1–4 The current 
concepts of NMOSD are rapidly changing. An interna-
tional panel of experts published the latest NMOSD diag-
nostic criteria in 2015.5 Pathogenic serum autoantibodies 
against aquaporin-4 (AQP4- IgG), an astrocytic water 
channel protein, can be detected in 60%–80% of patients 
with NMOSD.6 7 The diagnostic criteria differentiate 
patients with positive or negative/unknown AQP4- IgG 
status. In the latter case, strict rules apply to the clinical 
presentation and paraclinical findings, in particular those 
from MRI for diagnosing NMOSD.5 8 In some AQP4- IgG 
seronegative patients within the NMO disease spectrum, 
for example with isolated recurrent ON or myelitis, serum 
antibodies against myelin oligodendrocyte glycopro-
tein (MOG) can be detected.9–12 As a different cellular 
target is involved, most experts consider MOG- IgG auto-
immunity, or MOG- IgG- associated encephalomyelitis, as 
a separate disease entity, pathogenetically distinct from 
classic AQP4- IgG- associated NMOSD.13–15 The term 
myelin oligodendrocyte glycoprotein antibody disease 
has recently been proposed for this disorder.16
ON is one of the most common clinical manifestation 
of NMOSD. It frequently results in severe structural optic 
nerve damage and visual impairment, often occurs bilat-
erally, with common relapses.3 17 18 Patients often develop 
a visual disability as a result of decreased high- contrast 
visual acuity (HCVA) and low- contrast visual acuity, as well 
as colour and visual field defects. These functional limita-
tions result in impaired vision- related quality of life and a 
high incidence of legal blindness.19–21
Optical coherence tomography (OCT) acquires high- 
resolution retinal images and plays an important role in 
assessing ON- associated damage in NMOSD22 and other 
neuroinflammatory disorders associated with ON.23 24 
After transection of optic nerve axons following acute 
ON, retrograde neurodegeneration leads to neuroaxonal 
damage in the retina.25
Retinal post- inflammatory neuroaxonal degeneration 
typically progresses for about 6 months after the onset of 
acute idiopathic ON. It can be assessed by OCT as peri-
papillary retinal nerve fibre layer thickness (pRNFL) or 
ganglion and inner plexiform layer thickness (GCIP).26 
Due to the rarity of NMOSD, adequate disease- specific 
studies on temporal ON dynamics are scant.27 Thus, it 
remains uncertain which time frame accurately reflects 
the disease. For example, in a recent population- based 
study of all acute ON in Southern Denmark, there was 
not a single AQP4- IgG seropositive case and only two 
with MOG- IgG in the 50 patients presenting with de novo 
acute ON during study duration.28 In MOG- IgG seropos-
itive patients, ON appears to be milder than in patients 
with detectable AQP4- IgG29 and leads to a better outcome 
despite equally severe retinal thinning.30 However, 
MOG- IgG seropositive patients display a higher relapse 
frequency, potentially leading to comparable cumulative 
retinal damage and loss of vision in the two subgroups.31 32 
Furthermore, MOG- IgG seropositive patients have a more 
pronounced pRNFL thinning in the temporal quadrant, 
while temporal and nasal quadrants are equally affected 
in AQP4- IgG positive disease.19 33 It is currently unclear, to 
what extent the retina and vision are affected by NMOSD 
independently of ON.22 In multiple sclerosis (MS), disease- 
associated and progressive neurodegeneration can occur 
in eyes unaffected by ON.34 35 Studies of NMOSD have led 
to conflicting results. ON in NMOSD tends to be more 
posterior and closer to the chiasm than that occurring 
in MS, and chiasmal affection could lead to carry- over 
effects in the less affected companion eye.36 37 However, 
recently described microstructural changes in the retina 
also suggest a primary retinopathy in NMOSD.38–41 This is 
potentially mediated by AQP4- expressing retinal Müller 
cells and could be independent of ON. Longitudinal data 
demonstrating progressive GCIP loss in AQP4- IgG posi-
tive patients with NMOSD independent of ON further 
supports this notion.42 43 These observations remain 
to be independently confirmed. In contrast, a recent 
exploratory longitudinal study in MOG- IgG seropositive 
patients suggested only progressive RNFL loss but not 
longitudinal GCIP reduction.44
Besides neuroaxonal damage, macroscopic retinal 
findings have been reported in NMOSD. Macular micro-
cysts occur in the inner nuclear layer and are associ-
ated with severe ON in approximately 20% of patients 
with NMOSD.45–47 Pathology and clinical significance of 
macular microcysts, sometimes called microcystic macular 
oedema, remain unclear; however, macular processes 
appear to occur more frequently than other processes 
such as vitreous traction, which was found in one MOG- 
IgG positive patient with microcysts.48
Investigating OCT for clinically and pathologically mean-
ingful information is hampered by the rareness and hetero-
geneity of NMOSD.49 In 2015, the Guthy Jackson Charitable 
Foundation International Clinical Consortium (GJCF- ICC) 
agreed to establish an image repository platform (neuromy-
elitis optical imaging repository (NOIR)), the purpose of 
which is to facilitate multinational and multicentre neuroim-
aging studies in NMOSD. NOIR is intended to help identify 
imaging pitfalls in NMOSD, develop and clinically validate 
imaging biomarkers of the disease, clinical disability and to 
define imaging endpoints for clinical trials. Here we report 
the outcome of the Collaborative OCT in NMOSD reposi-
tory study (CROCTINO) as the initial effort in establishing 




The study was designed as a multinational and multicentre 
repository study collecting longitudinal OCT data as well 
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as relevant clinical data from patients with NMOSD and 
healthy controls (HCs). Participating centres were asked 
to contribute both retrospective and prospective data 
that was collected over a defined period extending from 
2000 to 2018. Scientific coordination and OCT reading 
were performed at the Charité—Universitätsmedizin 
Berlin Translational Neuroimaging Group. Partici-
pating centres were mainly recruited from the GJCF- ICC, 
which includes international researchers and clinicians 
focusing on NMOSD. Additional experts who had previ-
ously published studies using OCT in NMOSD but who 
were not members of the GJCF- ICC were contacted 
and invited to participate. For this purpose, a question-
naire screening each centre for the number of eligible 
patients and the type of OCT instruments used at their 
site was sent to the entire GJCF- ICC and to other iden-
tified experts. Centres giving a positive response to the 
recruitment questionnaire received further instructions 
on how to contribute OCT images and the associated 
demographical and clinical data of their patients and 
HCs. The overall study design—including the workflow—
is illustrated in figure 1.
Inclusion and exclusion criteria
Subjects were included with (a) a diagnosis of NMOSD 
as specified by the 2015 International Panel criteria5 or 
(b) longitudinal extensive transverse myelitis and/or (c) 
recurrent ON or (d) HCs (without matching require-
ments). OCT source data, demographic and clinical 
metadata from patients and HCs were required, including 
age, sex, disease subtype, autoantibody status and clinical 
history including details of ON.
Data collection and workflow
All demographic and clinical data were assessed in an 
electronic repository based on Research Electronic Data 
Capture (REDCap),50 located at the University of Utah 
Data Coordination Center. OCT images were transferred 
by participating centres via TeamBeam (Skalio GmbH, 
Hamburg, Germany), a commercial web- based medical 
data exchange service certified for secure data transfer. 
OCT images were then stored and analysed using a secure 
server at Charité—Universitätsmedizin Berlin, Berlin, 
Germany.
Study preparation began in January 2016 by identifying 
potential participating centres, setting up the informa-
tion technology (IT) infrastructure and developing the 
electronic case report forms (eCRFs) in REDCap. eCRFs 
were sent to all participants for review and were revised 
accordingly. The data collection was launched on 1 
September 2016, when the final repository was released, 
and centres received REDCap accounts for data entry. 
Data collection officially closed on 30 September 2018. 
After a detailed plausibility check, identified missing data 
could be submitted until 31 December 2018. A detailed 
timeline is illustrated in figure 2.
Collected dataset
The data elements that were collected are listed in online 
supplemental file 1 (including indications of which 
data elements were mandatory or optional) and are 
summarised as follows:
Demographic and clinical data
In addition to age and sex, ethnicity was assessed based 
on published NIH categories (https:// grants. nih. gov/ 
grants/ guide/ notice- files/ not- od- 15- 089. html). Possible 
selections comprised ‘American Indian or Alaska Native’, 
‘Asian’, ‘Black or African American’, ‘Hispanic or Latino’, 
‘Native Hawaiian or Other Pacific Islander’, ‘White’ and 
‘Other’; up to two selections were possible. Height and 
weight were collected. Information concerning the pres-
ence of ophthalmological comorbidities other than those 
related to NMOSD was requested. The possible answers 
were: ‘Unknown’, ‘No (excluded by examination)’, 
‘No (excluded by history taking)’ and ‘Yes’. In case of 























































Figure 1 Flow chart explaining the overall study design 
and information technology (IT) infrastructure. DCC, Data 
Coordinating Center; OCT, optical coherence tomography; 
REDCap, Research Electronic Data Capture; SAMIRIX is 
a custom- developed intraretinal segmentation pipeline55. 
OSCAR- IB are validated consensus quality criteria for retinal 
OCT reading53.
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the presence of other comorbidities was assessed. Infor-
mation about NMOSD diagnosis was mandatory, with 
possible selections of ‘NMO (2006 criteria)’, ‘AQP4- IgG 
seropositive NMOSD (2015 criteria)’, ‘AQP4- IgG sero-
negative NMOSD (2015 criteria)’, ‘MOG- IgG- associated 
encephalomyelitis/NMOSD’, ‘RON/CRION (Recur-
rent Optic Neuritis)’, ‘LETM (Longitudinal Extensive 
Transverse Myelitis)’. We inquired about the AQP4 and 
MOG antibody statuses separately (both mandatory) with 
possible answers ‘Seropositive’, ‘Currently seronegative, 
but at least one previous test was positive’, ‘Seronegative’, 
‘Not known/Never assessed’. Patients were considered to 
be seropositive for AQP4- IgG or MOG- IgG if antibodies 
were detected in at least one assay. Centres were also 
asked which assay they used for antibody testing. Provi-
sion of the Expanded Disability Status Scale (EDSS) score 
was optional.51 History of clinical attacks was requested 
with a focus on ON. Information concerning each eye was 
recorded separately as was the number of ON attacks and 
date of last episode. History of other NMOSD defining 
attacks, such as transverse myelitis, area postrema 
syndrome, brainstem syndromes, symptomatic narcolepsy 
or acute diencephalic clinical syndrome with NMOSD- 
typical diencephalic MRI lesions, and symptomatic cere-
bral syndrome with NMOSD- typical brain lesions was 
requested without dates and with the option ‘unknown’. 
Immunotherapy was assessed with a selection of common 
NMOSD treatments52 and possible selections ‘Current’ 
and ‘Previous use’.
Optical coherence tomography
Scans from all common OCT machines were accepted, 
resulting in scans from three different types of machines: 
(a) Spectralis SD- OCT (Heidelberg Engineering, Heidel-
berg, Germany), (b) Cirrus HD- OCT (Carl Zeiss Meditec, 
Dublin, California, USA) and (c) Topcon 3D OCT-1 
(Topcon, Tokyo, Japan). We requested that centres 
upload two scan types per eye from each visit:
 ► A peripapillary ring scan with 12° or approximately 
3.4 mm diameter around the optic disc. For those 
using Cirrus and Topcon, an optic disc volume scan 
was uploaded since peripapillary data are extracted 
from this scan.
 ► A macular volume scan, centred on the fovea, with 
a minimum size of 20°×20° (approximately 6 mm×6 
mm).
There were no restrictions regarding OCT image 
averaging or quality. At least one scan per visit was 
required to be included in the repository. After images 
were transferred, their quality was assessed based on 
modified OSCAR- IB criteria.53 54 Modifications were 
made for better applicability to macular scans (see 
online supplemental file 2). pRNFL segmentation was 
performed with device- internal algorithms, intraretinal 
layer segmentation with a device- independent segmen-
tation pipeline.55
Visual function
HCVA was requested with a selection menu ranging from 
20/10 (−0.3 logMAR) to ‘no light perception’. Informa-
tion on the method of testing was not requested, but 
details of whether testing was performed best corrected, 
habitually corrected or uncorrected were recorded. 
Monocular HCVA was mandatory while binocular HCVA 
was optional. Additionally, low contrast letter acuity 
(LCLA) from 2.5% contrast Sloan charts, normal/
abnormal classifications of visual evoked potentials 
(VEP) P100 latencies and mean deficit and pattern stan-
dard deviation from visual fields could be entered as 
optional information.
Statistical analysis
Cohort and statistical description for this cohort profile 
were performed with R V.3.4.456 in R Markdown and 
RStudio (RStudio, Boston, Massachusetts, USA).
Figure 2 Detailed study timeline including all study phases with start and end dates, as well as a brief description of each 
phase. eCRFs, electronic case report forms; OCT, optical coherence tomography.
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Cohort overview
Centres from North and South America, Asia and Europe 
participated in CROCTINO. In total, data from 539 
patients from 22 centres and 114 HCs from 5 centres were 
collected. Centres and the size of their patient and HC 
cohorts are listed alphabetically in table 1.
In total, we collected 1868 peripapillary ring scans/
optic nerve volume scans and 1672 macular volume scans 
fulfilling defined specifications. Only scans with corre-
sponding clinical data were considered. Device and scan 
specifications are depicted in table 2.
A cohort characterisation is depicted in table 3. The 
mean patient age (mean±SD) was 43.1±14.8 years with 
444 (82%) women. The age of HCs (mean±SD) was 
32.1±9.8 years with 72 (63%) women. The majority of 
patients were White or Middle Eastern (n=315), followed 
by Asian (n=128) and Black or African American (n=27).
Among all patients, 515 (95.5%) fulfilled the 2015 
diagnostic criteria for NMOSD.5 Of those not meeting 
the 2015 criteria, 21 (3.9%) carried the diagnosis of 
LETM, and 3 (0.6%) recurrent ON. Among those 
fulfilling NMOSD diagnostic criteria, 369 (72%) were 
AQP4- IgG seropositive, leaving 146 (28%) with negative 
or unknown AQP4- IgG status. Among the AQP4- IgG 
seronegative patients, 54 (37%) were MOG- IgG sero-
positive, 34 (23%) were double- negative for AQP4- IgG 
and MOG- IgG and 58 (40%) had an unknown antibody 
status. In the entire cohort, 369 (68%) were AQP4- IgG 
seropositive, 54 (10%) MOG- IgG seropositive, 52 (10%) 
had double negative and 64 (12%) had an unknown 
antibody status. There were 400 (74%) patients with at 
least one episode of ON, and 410 (76%) patients with 
a history of myelitis. The mean time since disease onset 
(mean±SD) was 5.47±19.47 years and mean age at initial 
symptom onset (mean±SD) was 36.18±15.05 years. Infor-
mation about current N,N- Dimethyltryptamine (DMT) 
was available in 398 (74%) patients. Ninety- seven patients 
(18.0%) received a combination of multiple DMTs. Most 
frequent DMT options comprised rituximab (n=128; 
24%), azathioprine (n=121; 22%), oral prednisolone 
(n=98; 18%), mycophenolate mofetil (n=77; 14%) and 
methotrexate (n=11; 2%).
Table 1 Participating centres with number of patients, 
number of HCs and used OCT device
Centre Patients HC OCT device
Bangkok, Thailand 25 0 Cirrus
Barcelona, Spain 13 13 Spectralis or Cirrus
Belo Horizonte, Brazil 57 0 Spectralis
Berlin, Germany 76 39 Spectralis
Duesseldorf, Germany 11 28 Spectralis
Goyang- si, Korea 50 0 Topcon OCT
Isfahan, Iran 40 18 Spectralis
Istanbul, Turkey 8 0 Cirrus
Liverpool, UK 8 0 Spectralis
Lyon, France 10 0 Spectralis
Mangalore, India 40 16 Spectralis
Maracaibo, Venezuela 3 0 Spectralis
Michigan, USA 5 0 Spectralis
Milan, Italy 30 0 Spectralis
Munich, Germany 11 0 Spectralis
New York, USA 6 0 Spectralis and Cirrus
Odense, Denmark 9 0 Spectralis
Oxford, UK 48 0 Spectralis
Petah- Tikva, Israel 25 0 Cirrus
Sao Paulo, Brazil 9 0 Spectralis
Seattle, USA 30 0 Cirrus
Strasbourg, France 25 0 Spectralis
HC, healthy control; OCT, optical coherence tomography.
Table 2 Technical and scan specifications
Protocol* Axial resolution (µm) Acquisition (A- scans/s) n B- scans A- scans per B- scan Size (mm)†
Spectralis Mac-1 3.962 40 00062 651 61 768 6×6
Spectralis Mac-2 240 25 512 6×6
Spectralis Mac-3 225 25 1024 7.5×9
Spectralis Ring-1 1143 1 1536 3.4
Spectralis Ring-2 226 1 768 3.5
Cirrus Mac 5.063 27 00063 293 128 512 6×6
Cirrus Ring 388 200 200 6×6/3.4‡
Topcon Mac 6.064 50 00064 263 128 512 6×6
Topcon Ring 111 128 512 6×6/3.4‡
*Only protocols making up more than 5% of the total macular scan rates were considered.
†Scan size can vary as it depends on the eye length.
‡Peripapillary ring scan extracted from optic nerve head volume scan.
Mac, macular volume.
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The majority of the centres provided OCT source data 
from a Spectralis machine (17 centres), followed by Cirrus 
(6 centres) and one centre contributed Topcon OCT images 
(table 1).
HCVA was available for 529 (98%) patients and 83 
(73%) HCs. Most of the patients received best- corrected 
HCVA (47%), 28% were habitually corrected and 25% 
not corrected. LCLA was obtained from 99 (18%) patients 
and 40 (35%) HCs. VEP were available for 177 (33%), 
and visual fields for 90 (17%) patients applying devices at 
the discretion of each centre.
Longitudinal data were available for 157 (29%) patients 
from 11 centres. Mean follow- up time (mean±SD) was 27±17 
months.
Patient and public involvement
Patients and the Public were not explicitly involved in 
the design or conduct of this study. However, the results 
of this study will be presented on a Guthy- Jackson Char-
itable Foundation’s International NMO Patient Day, 
giving patients, relatives and researchers the opportunity 
to share ideas for projects based on this cohort.
Findings to date
To our knowledge, the CROCTINO repository comprises 
the largest dataset on retinal OCT in NMOSD. Cohort 
demographics are in line with previous epidemiological 
NMOSD studies: gender ratio, age at symptom onset 
and prevalence of AQP4- IgG and MOG- IgG antibodies 
are similar to previously published studies and suggest a 
cohort that is representative of the disease spectrum.57–59 
OCT quality and quantitative analyses are currently being 
investigated as first scientific derivatives of the work and 
will be published in the near future. During the study, 
many challenges in conducting an investigator- driven 
academic repository study were experienced. First, this 
study was implemented without centre reimbursement. 
While we are unaware of specific guidelines in this regard, 
we felt that data quality would potentially be higher when 
centres receive no reimbursement. Although without 
reimbursement we expected a lower motivation for 
interested centres to participate at all, we reckoned that 
data quality might be higher from participating centres 
contributing out of sole scientific interest. Despite the 
absence of financial compensation, centre motivation was 
excellent, and we were able to include substantially more 
datasets (n=539) than initially anticipated (n=200). Lack 
of reimbursement did preclude the participation of some 
centres, particularly in North America. Sharing of data 
requires legal compliance, including the conclusion of 
data transfer agreements (DTA). Although we provided 
an initial DTA template for this study, almost all centres 
required modifications, the consequence of different 
legal systems in this multinational setting. This process 
resulted in a substantially delayed data collection. On the 
other hand, the DTA templates for each of the involved 
centres in combination with concluded DTA for this 
repository now provide a powerful platform and network 
for future studies in NMOSD.
During the conduct of this study, we developed several 
technical solutions, which will be made available beyond 
the scope of this repository. First, the technical infrastruc-
ture and newly established workflows will be instrumental 
in conducting future neuroimaging studies in NMOSD. 
We further developed a device- independent intraretinal 
layer segmentation pipeline based on an established 
segmentation algorithm.60 This pipeline is capable of 
importing and segmenting OCT scans from all devices 
included in the study and will presumably lead to better 
comparability of OCT data obtained from different 
devices.55 Finally, we modified the widely used OSCAR- IB 
criteria53 for assessing OCT image quality to be appli-
cable to macular volume scans and all OCT devices. The 
modified criteria will be validated using data from our 
repository.
Table 3 Cohort description
Healthy 
controls Patients
Subjects (n) 114 539
Centres (n) 5 22
Age (years; mean±SD) 32.1±9.8 43.1±14.8
Sex (woman; n (%)) 72 (63.2) 444 (82.4)
Time since disease onset (years; 
mean±SD)
– 5.5±19.5





White or Middle 
Eastern
96 (84.2) 315 (58.4)
Asian 17 (14.9) 128 (23.7)
Black or African 
American
0 (0) 27 (5.0)
Hispanic or Latino 1 (0.9) 11 (2.0)
Other 0 (0) 23 (4.3)
Not reported 0 (0) 35 (6.5)
Patients fulfilling the 2015 
diagnostic criteria for NMOSD 
(fulfilled; n (%))
– 515 (95.5)
AQP4- IgG seropositive NMOSD 
(n (%))
– 369 (68.5)
MOG- IgG seropositive NMOSD 
(n (%))
– 54 (10.0)
Double- negative NMOSD (n (%)) – 34 (6.3)
NMOSD with unknown antibody- 
status (n (%))
– 58 (11.0)
Patients with a history of optic 
neuritis (n (%))
– 400 (74.2)
Patients with a history of myelitis 
(n (%))
– 410 (76.1)
AQP4- IgG, aquaporin-4 IgG antibodies; MOG- IgG, myelin 
oligodendrocyte glycoprotein IgG antibodies; NMOSD, 
neuromyelitis optica spectrum disorders.
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Strengths and limitations
With 539 patients, CROCTINO comprises the largest 
dataset of OCT images from patients with NMOSD that 
we are aware of. The cohort resembles epidemiological 
studies published earlier and includes relevant demo-
graphic and clinical data. Further, the autoantibody 
status is available for many datasets, including not only 
AQP4- IgG but also MOG- IgG, thus distinguishing this 
cohort from many earlier studies where MOG- IgG was 
either unknown or unavailable. Inclusion of different 
ethnicities and geographical regions should allow analysis 
and comparison with patients with NMOSD in different 
cohorts, who are usually investigated only in smaller 
separate analyses from one or few centres. Finally, this 
study collected raw OCT imaging data thereby allowing 
detailed quality reading and image analysis, also with 
advanced technologies in the future.
The study has several limitations, many of which are 
inherent to multicentre settings. First, the inclusion 
of retrospective data precluded application of a stan-
dardised, homogeneous imaging protocol. Hetero-
geneity in the dataset is further caused by (a) use of 
different OCT machines, (b) different scan protocols 
and (c) no homogeneous visual function measures. 
Several geographic regions are not represented in the 
repository (eg, Australia, Africa), and HC scans are not 
matched demographically and are only available for 
some ethnicities and from certain regions. Although 
great care was taken in collecting, completing and veri-
fying the data, we could not ensure complete individual 
data set validity. For example, different methods for 
antibody testing61 with often uncertain sensitivity and 
specificity and a non- standardised documentation of 
patient- reported information could lead to some noise 
in respective analyses.
Collaboration and future directions
The study coordinating centre is pursuing several scien-
tific projects based on the repository in collaboration 
with the participating centres, such as the analysis of 
pRNFL and intramacular layer thickness measurements 
in this cohort in an attempt to identify differences 
between distinct disease phenotypes, demographics 
and ethnicities. We encourage collaboration with inter-
ested researchers in additional scientific projects. 
The CROCTINO dataset will be made available to all 
participating centres and to qualified investigators on 
request (details see below). The study coordinators are 
also interested in further expanding the repository by 
including (a) additional data from currently underrep-
resented geographic regions, (b) additional HC data to 
provide expanded ethnicity comparators and (c) more 
prospective, longitudinal data, also extending already 
existing follow- up periods of the included patients. The 
established NOIR platform and the CROCTINO cohort 
will serve to investigate retinal imaging biomarkers in 
NMOSD in the future.
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